Skip to main content

Table 2 Descriptive and comparative statistics of the different studied parameters in the different patient subgroups

From: Growth differentiation factor 15: an emerging diagnostic biomarker of liver fibrosis in chronic hepatitis C patients

Parameter

Liver fibrosis patient group (n = 55)

Kruskal-Wallis test

Subgroup І F0-F1

Subgroup II F2

Subgroup III F3–F4

H

p value

n.

Median

Q1–Q3

n.

Median

Q1–Q3

n.

Median

Q1–Q3

Age (years)

16

32

28–47.25

12

37.5

32–47.5

22

52.5

43.75–57.5

12.522

0.002

Weight (kg)

18

73.5

68–78.25

13

75

67.5–86.5

24

70

66.5–84.5

0.273

0.873

AST (IU/L)

18

28

21–36.25

13

25

19–43

24

50.5

8.75–72.5

20.873

0

ALT (IU/L)

18

27

20.25–43.5

13

35

21.5–48

24

47

35.5–64.25

9.367

0.009

T. bilirubin (mg/dl)

18

0.65

0.475–0.8

13

0.6

0.35–0.8

24

1

0.8–1.75

16.122

0

D. bilirubin (mg/dl)

18

0.2

0.1–0.2

13

0.2

0.1–0.3

24

0.3

0.2–0.7

13.276

0.001

Albumin (g/L)

17

4.1

3.95–4.45

13

4.2

4–4.5

24

3.55

3.2–4.1

14.857

0.001

Platelets (10^3/ul)

18

232

188.25–256

13

256

219–295.5

24

135

91–223.75

15.835

0

INR

18

1

0.987–1.025

13

1

1–1.1

23

1.1

1–1.3

10.895

0.004

AFP (IU/ml)

9

2.5

1.2–5.45

11

2.9

1.9–4.5

23

9.2

2.9–13.6

9.89

0.007

GDF-15 (ng/L)

18

340

220–500

13

500

405–510

24

415

335–587.5

5.185

0.075

  1. Q1–Q3* = interquartile range (25th–75th percentiles); p value > 0.05 is non-significant; p value < 0.01 is highly significant